1. In Vivo
  2. >>Growth

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

 
• By Stephanie Yip and Daniel Chancellor

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.    

vaccination
• Source: Shutterstock

Now that the books for 2021 are closed, In Vivo has crunched the numbers and can report on the best-selling pharmaceuticals last year. And what a year it was, with expectations for drug launches having been completely rewritten. Humira lost its record for peak annual drug sales, not to Keytruda as had seemed inevitable for the past couple of years, but to a product that transitioned from bench to bedside to $40bn+ dollars in under two years.

Pfizer Inc.’s Comirnaty, licensed from BioNTech SE, along with Moderna, Inc.’s mRNA COVID-19 vaccine Spikevax, capitalized on the once-in-a-generation (or longer?) opportunity by allying life-saving clinical data with tremendous manufacturing scale, aided by large government purchases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Financing Quarterly Statistics, Q1 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

More from In Vivo

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By Ashley Yeo

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.